BLCM Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today announced that senior management will participate in two upcoming healthcare investor conferences.

Conference Details:

Event: Citi’s 13th Annual Biotech ConferenceDate: Wednesday, September 5, 2018Location: Boston, MA

Event: 2018 Wells Fargo Securities Healthcare Conference Date/Time: Thursday, September 6, 2018 at 10:55 a.m. EDTLocation: Boston, MA

A live webcast of the presentation at Wells Fargo may be accessed from the News & Events section of the Bellicum website. An archived version of the webcast will be available for replay for at least two weeks following the event.

About Bellicum Pharmaceuticals Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. Bellicum is using its proprietary Chemical Induction of Dimerization (CID) technology platform to engineer and control components of the immune system. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR-T and TCR cell therapies. More information can be found at www.bellicum.com.

Source: Bellicum Pharmaceuticals

Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com

Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@troutgroup.com